Endo pain drug linked with blood disorder when abused; Novartis drops long-acting Fanapt;

@FiercePharma: How is the U.K.'s fund for NICE-nixed cancer drugs faring? Total spent since 10/2010: £180.9M on 18K+ patients. Report | Follow @FiercePharma

> Endo Pharmaceuticals' ($ENDP) painkiller Opana can trigger a potentially fatal blood disorder if crushed and injected, one common method of pain-drug abuse. Report

> Novartis ($NVS) dropped development of a long-acting version of the antipsychotic drug Fanapt, after sales of the original version failed to live up to initial enthusiasm. Report

> Boehringer Ingelheim's clot-dissolving drug Actilyse got a boost from U.K. cost-effectiveness watchdogs, who broadened the potential treatment window for stroke patients. Report

> A drug shortage led to a tenfold increase in IV-related infections in hospitalized children, a study found. Report

> Teva Pharmaceutical Industries ($TEVA) supplier Venus Remedies is expected to see increased growth as resistant germs spur depand for its antibiotic combo drugs. Report

Biotech News

 @FierceBiotech: Alzheimer's drug builds new brain cell connections in rats. Story | Follow @FierceBiotech

 @JohnCFierce: New FDA lung cancer OK for Celgene's Abraxane should boost sales. More | Follow @JohnCFierce

 @RyanMFierce: Biotech regulars should appreciate this: Actress Jennifer Aniston investing in a Bob Langer company. More | Follow @RyanMFierce

> Intercept Pharma, Kythera Bio jump out of the IPO gate. Story

> NPS Pharma shares jump on upbeat FDA review of Gattex. News

> Vertex's new data on CF drug cocktail doesn't disappoint. Report

 @FierceMedDev: Coming soon: we'll find out if Intuitive Surgical's earnings slowed in Q3 as predicted. Let the speculation begin. More | Follow @FierceMedDev

 @MarkHFierce: Medtech industry's efficiency reaches new level, PwC report concludes. Article | Follow @MarkHFierce

 @DamianFierce: A federal court has tossed Fresenius' $83M Medicare fraud judgement. More  | Follow @DamianFierce

> FDA approves aortic-repair stent grafts. Article

> As it turns to medtech, Sony's credit rating gets lowered. Report

And Finally... Younger women suffering from chemotherapy-related menopause may get aid from talk therapy and exercise, a study found. Report

Suggested Articles

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

In an interview with Israel's Calcalist, Teva CEO Kåre Schultz shared details of his approach to the company's turnaround.

Nerlynx is already struggling in its extended adjuvant breast cancer setting, and new entrants from Daiichi-AZ and SeaGen could pressure it elsewhere.